Table 1.
Demographic, clinical, pathological findings, surgical, and adjuvant treatment
| N | 48 |
|---|---|
| Age | 56.7 (10–90) years |
| Follow-up | 84 (60–130) months |
| Sex | |
| Male | 22 (46%) |
| Female | 26 (54%) |
| Site | |
| Right parotid gland | 22 (46%) |
| Left parotid gland | 26 (54%) |
| Histological diagnosis | |
| Carcinoma ex pleomorphic adenoma | 11 (22.9%) |
| Mucoepidermoid carcinoma | 8 (16.7%) |
| Acinic cell carcinoma | 7 (14.6%) |
| Salivary duct carcinoma | 6 (12.5%) |
| Adenoid cystic carcinoma | 4 (8.3%) |
| Epithelial-myoepithelial carcinoma | 3 (6.3%) |
| Adenocarcinoma, not otherwise specified (NOS) | 2 (4.2%) |
| Oncocytic carcinoma | 2 (4.2%) |
| Squamous cell carcinoma | 2 (4.2%) |
| Myoepithelial carcinoma | 1 (2.1%) |
| Polymorphous adenocarcinoma | 1 (2.1%) |
| Poorly differentiated carcinoma | 1 (2.1%) |
| Surgery—parotidectomy | |
| Partial parotidectomy | 20 (41.6%) |
| Total parotidectomy | 8 (16.7%) |
| Total parotidectomy + facial nerve resection | 5 (10.4%) |
| Extended parotidectomy + facial nerve sparing | 7 (14.6%) |
| Extended parotidectomy | 8 (16.7%) |
| Surgery—neck dissection | |
| No | 29 (60.4%) |
| Yes | 19 (39.6%) |
| During first surgery | 17 (35.4%) |
| Secondary surgery | 2 (4.2%) |
| Radiotherapy | |
| No | 23 (47.9%) |
| Yes | 25 (52.1%) |
| IMRT | 22 (45.8%) |
| Proton therapy | 3 (6.3%) |
| Chemotherapy | |
| No | 44 (91.7%) |
| Yes | 4 (8.3%) |
Italic values indicate titles